News & Updates

Dengue prevention is a national emergency in Malaysia as the incidence and deaths have been increasing year by year.

In the interim analysis of the pivotal phase III PURPOSE 1 trial, twice-yearly subcutaneous lenacapavir, a first-in-class, high-potency HIV-1 capsid inhibitor, shows 100-percent efficacy and superiority to background HIV (bHIV*) incidence and daily oral emtricitabine/tenofovir disoproxil fumarate (F/TDF**) for pre-exposure prophylaxis (PrEP) in HIV-negative cisgender women.

A new prediction score model identifies older patients with community-onset pneumonia who are nearing the end of life and need advance care planning (ACP) practices, reports a study.